Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adjuvants in perspective

F R Vogel1

  • 1Vaccine and Prevention Research Program, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.

Developments in Biological Standardization
|April 29, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The immunogenicity of a cell-derived H7N1 split influenza virion vaccine in mice.

Scandinavian journal of immunology·2009
Same author

Improving vaccine performance with adjuvants.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2000
Same author

Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120.

Journal of immunology (Baltimore, Md. : 1950)·1997
Same author

Workshop on the control and standardization of nucleic acid vaccines. Bethesda, Maryland, 8 February 1996.

Vaccine·1997
Same author

Role of adjuvants in HIV vaccine design.

Antibiotics and chemotherapy·1996
Same author

Nucleic acid vaccines.

Clinical microbiology reviews·1995
Same journal

International challenges and public policy issues.

Developments in biological standardization·2000
Same journal

Regulation of biologicals in China.

Developments in biological standardization·2000
Same journal

ICH activities on biotech topics.

Developments in biological standardization·2000
Same journal

Regulation of biologicals in the European Union.

Developments in biological standardization·2000
Same journal

Standardisation and licensing of combination vaccines based on DTP.

Developments in biological standardization·2000
Same journal

Control of foot-and-mouth disease by vaccination.

Developments in biological standardization·2000
See all related articles

Immunological adjuvants enhance immune responses to subunit vaccines, improving safety and efficacy. Selecting the right adjuvant is crucial for desired immune responses, with novel options under development for diseases like HIV-1.

Area of Science:

  • Vaccinology
  • Immunology
  • Biotechnology

Background:

  • Modern vaccines increasingly use synthetic, recombinant, or purified subunit antigens for improved safety profiles compared to traditional whole-cell or live-attenuated vaccines.
  • However, these subunit vaccines often exhibit lower immunogenicity, necessitating strategies to boost immune responses.
  • Immunological adjuvants are key components for enhancing the efficacy of subunit antigen-based vaccines.

Purpose of the Study:

  • To explore the role and mechanisms of immunological adjuvants in enhancing vaccine immunogenicity.
  • To discuss the selection criteria for adjuvants based on administration route and desired immune response (antibody, cell-mediated, mucosal).
  • To highlight the development of novel adjuvants and standardized safety testing for experimental vaccines, including those targeting HIV-1.

Related Experiment Videos

Main Methods:

  • Review of adjuvant mechanisms of action, including antigen half-life extension, improved antigen delivery/presentation, and induction of immunomodulatory cytokines.
  • Discussion on tailoring adjuvant formulations to modulate T-helper cell responses (Th1/Th2).
  • Overview of ongoing preclinical and clinical testing of novel adjuvants and development of standardized safety assays.

Main Results:

  • Adjuvants can significantly enhance immune responses to subunit antigens, addressing their inherent lower immunogenicity.
  • Adjuvants offer diverse mechanisms to boost vaccine efficacy, including pharmacokinetic modulation and immune cell activation.
  • Adjuvant formulation can direct the type of immune response, favoring Th1 or Th2 profiles.

Conclusions:

  • Formulating subunit vaccines with potent adjuvants is a critical strategy to improve immunogenicity and overall vaccine effectiveness.
  • Adjuvant selection must be guided by the specific vaccine's target and desired immune outcome.
  • Ongoing research into novel adjuvants and robust safety testing is vital for advancing next-generation vaccines, particularly for challenging targets like HIV-1.